"Nvidia's AI Partnerships Propel Stock 24% Higher, Wall Street Eyes Strategic Growth"

Nvidia's stock surged 24% as it continues to make strides in AI and life sciences, with partnerships with Meta, Recursion, and Amgen. Recursion's LOWE software and Prime Medicine's gene editing therapy faced fluctuations in stock prices, while Allakos announced a workforce reduction after its drug missed endpoints. Bullfrog AI's collaboration with LIBD yielded promising results in understanding and treating psychiatric disorders, leading to a significant increase in its stock price.